Oruka Therapeutics (NASDAQ:ORKA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Oruka Therapeutics (NASDAQ:ORKA) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

Other equities analysts have also issued reports about the company. Wedbush raised their target price on Oruka Therapeutics from $42.00 to $45.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. UBS Group initiated coverage on Oruka Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price objective on the stock. BTIG Research raised their price objective on Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a report on Thursday, November 13th. They issued a “buy” rating and a $45.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Oruka Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $54.50.

Oruka Therapeutics Trading Up 0.3%

Oruka Therapeutics stock opened at $34.41 on Friday. The company has a market capitalization of $1.67 billion, a P/E ratio of -18.11 and a beta of -0.38. The firm’s fifty day simple moving average is $32.26 and its 200-day simple moving average is $26.25. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $36.53.

Insider Buying and Selling at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total transaction of $226,590.00. Following the transaction, the insider owned 34,018 shares of the company’s stock, valued at approximately $1,101,162.66. The trade was a 17.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold 21,000 shares of company stock valued at $663,530 over the last three months. 24.69% of the stock is currently owned by corporate insiders.

Institutional Trading of Oruka Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ORKA. Financial Enhancement Group LLC bought a new stake in Oruka Therapeutics in the 3rd quarter valued at $631,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in shares of Oruka Therapeutics during the 3rd quarter worth about $296,000. B Group Inc. boosted its position in shares of Oruka Therapeutics by 28.8% during the 2nd quarter. B Group Inc. now owns 75,000 shares of the company’s stock valued at $841,000 after acquiring an additional 16,785 shares in the last quarter. Geode Capital Management LLC increased its stake in Oruka Therapeutics by 100.6% in the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after acquiring an additional 354,821 shares during the period. Finally, Affinity Asset Advisors LLC increased its stake in Oruka Therapeutics by 10.7% in the second quarter. Affinity Asset Advisors LLC now owns 603,479 shares of the company’s stock valued at $6,765,000 after acquiring an additional 58,117 shares during the period. 56.44% of the stock is currently owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.